Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Noa Cleveland"'
Publikováno v:
Inflammatory bowel diseases. 28(8)
Autor:
Noa Cleveland, Benjamin Chastek, Tito Ghosh, Ninfa Candela, Timothy Bancroft, Tao Fan, Kandavadivu Umashankar, David Rubin
Publikováno v:
Gastroenterology. 162:S8-S9
INTRODUCTION Inadequate response, loss of response, or intolerance to a first-line biologic typically requires patients with ulcerative colitis (UC) to switch treatment to a second-line biologic therapy. However, the clinical outcomes of patients rec
Autor:
Noa Cleveland, Ninfa Candela, John Carter, Maja Kuharic, Joyce Qian, Lily Tang, Robin Turpin, David Rubin
Publikováno v:
Inflammatory Bowel Diseases. 28:S105-S106
BACKGROUND Pivotal trials in ulcerative colitis (UC) have indicated that earlier intervention with a biologic is associated with greater likelihood of treatment response. However, in real-world clinical practice, patients with newly diagnosed UC are
Autor:
Nathaniel Cohen, Tenzin Choden, David Choi, Noa Cleveland, Russell Cohen, Sushila Dalal, Atsushi Sakuraba, Ira Hanan, David Rubin
Publikováno v:
Inflammatory Bowel Diseases. 28:S109-S109
BACKGROUND In May 2021 the United Stated Food and Drug Administration (FDA) approved the use of ozanimod for moderate to severe ulcerative colitis (UC) based on the results of the pivotal phase 3 TRUE NORTH trials. We present the first report of real
Autor:
Zmeter Nada, Buisson Anthony, Russell D. Cohen, Pekow Joel, Noa Cleveland Krugliak, Normatov Inessa, David T. Rubin, Katia El Jurdi, Glick Laura, Yvellez Olivia
Publikováno v:
American Journal of Gastroenterology. 113:S8
Prevalence of Micronutrient Deficiencies in Patients With Crohnʼs Disease Undergoing Ostomy Creation
Autor:
Noa Cleveland Krugliak, Ayal Hirsch, Andres Yarur, Dylan M. Rodriquez, David T. Rubin, Jennifer Labbas
Publikováno v:
American Journal of Gastroenterology. 110:S839